Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...

Australian pharmaceutical companies retreated in morning trade after shares in US pharma giant Eli Lilly dived 14% overnight, due disappointing data on its new oral weight loss pill.

A late-stage study tested three doses of Eli Lilly’s oral GLP-1 drug, Orforglipron, in more than 3,100 adults, with the ...

AM ET, the S&P 500 added 0.6%, the Dow Jones Industrial Average was up 0.4%, and the Nasdaq Composite was 1.1% higher.